- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the US (since October 2024) and EU (since November 2024), with expanded labels in both regions in mid-2026.
- Why 3/10
- Hympavzi is already approved and commercialized in both the US and EU with no pending PDUFA or pivotal readout in the next ~12 months. As an approved drug at a company with ~$60B+ in annual revenue, it lacks a hard binary catalyst that could drive a significant share-price move, capping the impact score at 3.
Hympavzi is already approved in both the US and EU for hemophilia A and B with and without inhibitors. No upcoming PDUFA or pivotal readout is scheduled in the next 12 months. The next catalyst to watch would be quarterly sales trajectory and any further label expansion (e.g., younger pediatric patients), but neither is a hard binary event. For a company the size of Pfizer, this drug is unlikely to be a standalone share-price driver.
Price Chart
Executive Summary
Hympavzi (marstacimab) is Pfizer's once-weekly subcutaneous monoclonal antibody for hemophilia A and B, approved by the FDA in October 2024 and expanded in June 2026 to cover patients ages 6 and older with or without inhibitors. The European Commission also approved it initially in November 2024 and expanded the label in May 2026. It is the first anti-TFPI therapy approved for both hemophilia subtypes. However, it enters a competitive market dominated by Roche's Hemlibra (emicizumab, ~$4-5B in sales) and faces additional competition from Sanofi's Qfitlia and Novo Nordisk's Alhemo. For Pfizer, a company guiding $60.5-62 billion in 2026 revenue, Hympavzi is one product among many and lacks a near-term binary catalyst.
How It Works
Hympavzi is a monoclonal antibody (a lab-made protein) that blocks a natural clotting inhibitor called TFPI (tissue factor pathway inhibitor). By neutralizing TFPI, it helps restore the blood's ability to clot, reducing the risk of bleeding episodes in people with hemophilia A or B. It works independently of the missing clotting factor, so it can be used in patients with or without inhibitors (antibodies that neutralize standard factor replacement therapy). It is given as a once-weekly shot under the skin.
Trial Status
Approved based on the Phase 3 BASIS study (NCT03938792) in hemophilia A or B without inhibitors, and a separate Phase 3 study in patients with inhibitors. An open-label extension study is ongoing. The drug is commercially available in the US and EU.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA or pivotal readout identified in the next 12 months.
- Potential further label expansion to younger pediatric patients (under age 6) could be a future catalyst but no timeline is set.
- Quarterly sales trajectory and physician adoption data (e.g., Spherix surveys) are the main ongoing metrics to watch.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report